Discovery of auto-antibodies in Long-COVID

• Conditions: PASC; Post-infectioeuze ziekten; long-covid

• Registration Number: NL-OMON53317
• Lead Sponsor: Amsterdam UMC

Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2023-06-14
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 32

Inclusion Criteria

* Non-hospitalized individuals with prior confirmed diagnosis of severe acute
respiratory coronavirus 2 (SARS-CoV-2) infection by reverse
transcription-polymerase chain reaction testing or serology (wantai) testing
* No Long-Covid symptoms present before confirmed diagnosis of SARS-CoV-2
* Individuals with diagnosed PASC by an Amsterdam UMC post-covid physician
* Aged between 18-65 years

Exclusion Criteria

* Pregnancy
* Chronic illness (including orthopaedic, endocrinological, haematological,
malignant, gastrointestinal, neurological, muscle or inflammatory disorders)
likely to significantly impact on exercise performance

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Outcome parameters for autoantibody analysis by HuProt will be the presence of<br /><br>autoantibodies that are unique for the long-COVID patients in venous blood </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The binding of the recombinant antibodies to the antigens that we identified by<br /><br>HuProt analysis </p><br>